European Journal of Immunology · 1988 · 50 citations · 53 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCytotoxic T Lymphocyte ResponsesOncogenic VirusesT Cell Responses To TumorsTumor-associated AntigensCellular Immune Response To VirusesCellular ImmunotherapyImmunogenicity Of Tumor AntigensT-cell Immune ResponsesTumor Antigen ImmunogenicityTumor Antigen-specific Cytotoxic T Lymphocyte ResponsesTumor ImmunogenicityTumor-specific T Cell Activation
Abstract The present study elucidates the mechanism whereby viral xenogenization of highly metastatic ESb lymphoid tumor cells increases tumor immunogenicity and syngeneic tumor‐specific T cell responses in comparison to nonmodified tumor cells. It was found that the frequency of cytotoxic T lymphocytes specific for the ESb tumor‐associated transplantation antigen (TATA) and the cytotoxic anti‐tumor activity in bulk cultures of immune spleen cells were significantly increased (by factor 3 and 25, respectively) when using virus‐modified tumor cells. An amplified response was observed both in vivo and in vitro which might explain the demonstrated effectiveness of this approach for postoperative immunotherapy of ESb metastases. For the stimulation of tumor‐specific cytolytic T lymphocytes (CTL) the ESb tumor cells which are highly metastatic were infected with an avirulent strain of the paramyxovirus Newcastle Disease Virus (NDV). Infection of ESb cells with low amounts of NDV was sufficient to lead to an increase in cytolytic activity of tumor‐specific CTL after sensitization in vivo and restimulation in vitro. In a sensitive limiting dilution mixed leukocyte‐tumor cell microculture system the direct effect of viral modification on the frequency and specificity of CTL was investigated. The number of ESb‐specific CTL per spleen could be raised from about 3300 (without modification) to 9100 by both in vivo and in vitro application of ESb‐NDV. One appliction of ESb‐NDV ( in vivo or in vitro ) increased the number of CTL to 4900 and 4600, respectively. In split‐type experiments it could be shown at the clonal level that viral modification did not alter the specificity of ESb‐specific CTL. No CTL clones directed against viral antigens or new antigenic determinants were detected. The results indicate that in this system the effect of viral xenogenization is not due to recognition of additional xenoor neoantigens. NDV modification instead led to a selective augmentation of the TATA‐specific CTL response. In this respect it is remarkable since other methods to increase ESb tumor immunogenicity such as mutagenization or co‐expression of minor H antigens were shown before to activate additional CTL clones without affecting the TATA‐specific CTL response.
53
T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity
Steven Gillis, Mary M. Ferm, Winny Ou et al. · The Journal of Immunology · 1978 · 3.3K citations · Full text
Deno P. Dialynas, Zou Quan, Katherine A. Wall et al. · The Journal of Immunology · 1983 · 1.3K citations
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
Stephen Cobbold, A. Jayasuriya, Anthony A. Nash et al. · Nature · 1984 · 874 citations